Immunogenic composition
AssigneeGlaxosmithkline Biologicals SA
InventorsRalph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
Life of this patent
Estimating the term…
Abstract
present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.
Claims4
An immunogenic composition, comprising N. meningitidis capsular polysaccharides from serogroups A, C, W, and Y, wherein:
- the serogroup A capsular polysaccharide has an average size of 300 kDa;
- the serogroup C capsular polysaccharide has an average size of 200 kDa;
- the serogroup Y capsular polysaccharide has an average size of 101-300 kDa;
- the serogroup W capsular polysaccharide has an average size of 101-300 kDa;
- and
- wherein each N. meningitidis capsular polysaccharide is a N. meningitidis capsular polysaccharide conjugate comprising a N. meningitidis capsular polysaccharide conjugated to a tetanus toxoid carrier protein.
An immunogenic composition, comprising N. meningitidis capsular polysaccharides from serogroups A, C, W, and Y, wherein:
- each of serogroups A, W, and Y capsular polysaccharide has an average size of 101-300 kDa,
- the serogroup C capsular polysaccharide has an average size of 200 kDa, and
- wherein each N. meningitidis capsular polysaccharide is a N. meningitidis capsular polysaccharide conjugate comprising a N. meningitidis capsular polysaccharide conjugated to a tetanus toxoid carrier protein.
Dependencies are inferred from the claim text.